# Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

> **NCT02177838** · NA · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 8 (actual)

## Conditions studied

- Stage III Squamous Cell Carcinoma of the Hypopharynx
- Stage III Squamous Cell Carcinoma of the Larynx
- Stage III Squamous Cell Carcinoma of the Oropharynx
- Stage III Verrucous Carcinoma of the Larynx
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IVA Squamous Cell Carcinoma of the Larynx
- Stage IVA Squamous Cell Carcinoma of the Oropharynx
- Stage IVA Verrucous Carcinoma of the Larynx
- Stage IVB Squamous Cell Carcinoma of the Larynx
- Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Stage IVB Verrucous Carcinoma of the Larynx
- Tongue Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin
- **RADIATION:** external beam radiation therapy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02177838
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-25
- **Primary completion:** 2019-08-22
- **Final completion:** 2019-08-22
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2021-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177838, "Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT02177838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*